Payment overview · 2025
General Payments
$356.04
16 reported records · 5 companies
Healthcare provider profile · identity verified
Hector Descamps, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · MIAMI, FL · NPI 1902851751
Verified facts
What the public records show
CMS Open Payments records show Hector Descamps, ARNP received $356.04 in general payments during 2025 across 16 reported records.
Aimmune Therapeutics, Inc. accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $171.83 | 48.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.36 | 21.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.98 | 17.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.96 | 8.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.91 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.04 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $171.83 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.36 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.98 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.49 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 82 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 220 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
220 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 309 | 61 |
| Gabapentin | Gabapentin | 283 | 52 |
| Montelukast Sodium | Montelukast Sodium | 259 | 42 |
| Famotidine | Famotidine | 224 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 222 | 54 |
| Linzess | Linaclotide | 220 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 44 |
| Omeprazole | Omeprazole | 187 | 43 |
| Ibuprofen | Ibuprofen | 185 | 45 |
| Ammonium Lactate | Ammonium Lactate | 161 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 25 |
| Glimepiride | Glimepiride | 115 | 18 |
| Lovastatin | Lovastatin | 115 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 17 |
| Losartan Potassium | Losartan Potassium | 105 | 25 |
| Alendronate Sodium | Alendronate Sodium | 104 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 98 | 24 |
| Meclizine Hcl | Meclizine Hcl | 98 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 87 | 14 |
| Metformin Hcl | Metformin Hcl | 86 | 18 |
| Lisinopril | Lisinopril | 85 | 21 |
| Creon | Lipase/Protease/Amylase | 82 | 27 |
| Eliquis | Apixaban | 81 | 12 |
| Methylprednisolone | Methylprednisolone | 78 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 15 |
| Furosemide | Furosemide | 72 | 14 |
| Mupirocin | Mupirocin | 72 | 35 |
| Pentoxifylline | Pentoxifylline | 70 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 12 |
| Zenpep | Lipase/Protease/Amylase | 65 | 11 |
| Finasteride | Finasteride | 64 | 14 |
| Cefdinir | Cefdinir | 63 | 40 |
| Allopurinol | Allopurinol | 61 | suppressed |
| Carvedilol | Carvedilol | 60 | 13 |
| Celecoxib | Celecoxib | 60 | 11 |
| Entresto | Sacubitril/Valsartan | 60 | 15 |
| Ozempic | Semaglutide | 60 | 14 |
| Bumetanide | Bumetanide | 57 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 56 | 36 |
| Farxiga | Dapagliflozin Propanediol | 55 | 13 |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 11 |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 31 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Nystatin | Nystatin | 40 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Ketoconazole | Ketoconazole | 38 | 15 |
| Ssd | Silver Sulfadiazine | 37 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Prednisone | Prednisone | 31 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Praluent Pen | Alirocumab | 30 | suppressed |
| Baclofen | Baclofen | 29 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | 11 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Mesalamine | Mesalamine | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $356.04 · 16 records | Aimmune Therapeutics, Inc. | AIRSUPRA, CREON, LEQVIO, LINZESS, OTEZLA, REPATHA, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error